(PPBT) Purple Biotech Ltd. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PPBT) Purple Biotech Ltd. Complete Analysis Pack
Unlock Strategic Clarity
This Purple Biotech Ltd. 4P's Marketing Mix Analysis explains the company’s product, pricing, distribution, and promotion in one concise framework and shows how their offering is used in the market; the page contains a real preview/sample of the analysis so you can judge style and substance before buying. Purchase the full version to get the complete ready-to-use report.
Product
Clinical-stage oncology pipeline
Purple Biotech Ltd. is a clinical-stage biotechnology company, so its “Product” is not a marketed drug but an oncology pipeline. The core offer targets hard-to-treat solid tumors and is designed to blunt tumor immune evasion and drug resistance. Its lead programs, including CM24 and NT219, were still in clinical development as of 2025, with no approved oncology sales yet.
CM24 anti-CEACAM1 antibody
CM24 is Purple Biotech Ltd.’s monoclonal antibody lead asset, built to block CEACAM1, a cancer immune-escape target. It is one of the Company’s two lead programs, so it sits at the center of Purple Biotech Ltd.’s product strategy. In 2025, Purple Biotech Ltd. reported a market value near $10 million, showing how much of the valuation rests on CM24 and the other lead asset.
CM24 Phase 1b/2 combinations
CM24 Phase 1b/2 combinations pair CM24 with anti-PD-1 checkpoint inhibitors in early clinical testing, aiming to boost response rates in immuno-oncology. The program is still in Phase 1b/2, so the key value is proof-of-concept rather than sales, and Purple Biotech Ltd. has not disclosed late-stage revenue from this asset. This mix targets a large, high-need cancer market where even modest response gains can matter.
NT219 small molecule
NT219 is Purple Biotech Ltd.'s clinical-stage small-molecule oncology candidate. It is designed to block IRS1, IRS2, and STAT signaling, which may help tumor cells evade treatment and grow under stress. That makes the product fit a niche need in resistant cancers, where even a modest response can matter.
- Targets resistance pathways inside tumors
- Small-molecule, drug-like format
- Built for oncology combination use
NT219 Phase 1/2 solid tumors
NT219 is Purple Biotech Ltd.'s Phase 1/2 oncology asset for recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. Its broad label matters: one program can target multiple tumor groups, which can widen the commercial market if efficacy and safety hold up in later studies.
- Phase 1/2 clinical stage
- Solid tumors plus HNSCC
- Multi-indication oncology use
Purple Biotech’s Pipeline: Early-Stage Oncology Bets, No Sales Yet
Purple Biotech Ltd.’s Product is a clinical-stage oncology pipeline, not a marketed drug, so value still depends on trial data. Its lead assets are CM24, a CEACAM1 antibody, and NT219, a small-molecule blocker of IRS1, IRS2, and STAT signaling. Both were still in early testing in 2025, with no approved sales.
| Asset | Stage | Focus |
|---|---|---|
| CM24 | Phase 1b/2 | Immune evasion |
| NT219 | Phase 1/2 | Resistance pathways |
What is included in the product
Detailed Word Document
A concise, company-specific 4P analysis of Purple Biotech Ltd.’s product, pricing, place, and promotion strategy.
Editable Excel File
Condenses Purple Biotech Ltd.’s 4Ps into a quick, clear view that eases analysis, alignment, and strategic planning.
Reference Sources
Provides a concise, traceable bibliography of industry reports, datasets, and benchmarks to speed due diligence and validate Purple Biotech Ltd.’s market, pricing, and unit-economics claims.
Place
Rehovot, Israel headquarters
Purple Biotech Ltd. is headquartered in Rehovot, Israel, and that base anchors its research and corporate work. The company runs a compact biotech model focused on R&D and clinical development, which fits a lean headquarters setup. Rehovot also keeps core decision-making close to Israel’s biotech talent and life-science cluster.
United States patient focus
Purple Biotech Ltd. targets U.S. cancer patients first, so the United States is the lead market for future approvals and launch plans. The focus fits the oncology trials it is running in U.S.-relevant indications, where the addressable market is large: the American Cancer Society projects about 2.0 million new U.S. cancer cases in 2025.
Clinical trial sites
Purple Biotech Ltd. reaches patients mainly through clinical trial sites, where investigational therapy is dispensed inside regulated studies. This is its core distribution channel while assets stay unapproved, so access is tightly controlled and limited to enrolled participants. That setup keeps compliance high, but it also caps scale until approval expands access.
Partner and investigator network
Purple Biotech Ltd. uses a B2B development model, so its partner and investigator network is the core of trial execution, not retail channels. The work sits with hospitals, principal investigators, CROs, and site teams that recruit patients, run protocols, and report data. For a clinical-stage biotech with no commercial sales, these partners are the main route to advancing programs.
Focus: investigators and trial sites
Support: CROs manage operations
Model: B2B, not retail
No retail pharmacy channel
Purple Biotech Ltd. has no retail pharmacy channel because it is still a clinical-stage company, not a commercial drug seller. Its assets are not sold through pharmacies, hospitals, or e-commerce as approved drugs, so access stays limited to research and trial settings. That means there is no consumer shelf presence and no retail-driven revenue stream.
- No approved drug sales.
- Availability is trial-only.
- No pharmacy or e-commerce footprint.
Purple Biotech’s reach runs through U.S. trial sites, not retail shelves
Purple Biotech Ltd. keeps Place centered on its Rehovot, Israel base, while U.S. clinical trial sites are the main access point for patients. As a clinical-stage company, its distribution is B2B through hospitals, investigators, and CROs, not retail. Until approval, access stays trial-only and scale stays capped.
| Place factor | Data |
|---|---|
| HQ | Rehovot, Israel |
| Primary market | United States |
| Channel | Clinical trial sites |
Preview Before You Purchase
Purple Biotech Ltd. Reference Sources
The preview shown here is the exact, full Purple Biotech Ltd. 4P's Marketing Mix analysis you’ll receive instantly after purchase—complete, editable, and ready to use with no surprises.
Promotion
Press releases
Purple Biotech uses press releases to flag pipeline updates, trial readouts, development milestones, and company changes. For a public clinical-stage biotech, this is a standard promotion channel because investors track catalysts more than sales. The latest releases matter most when they move the story on lead programs, data timing, or financing needs.
Scientific congresses
Scientific congresses let Purple Biotech Ltd. present its oncology data, mechanism, and clinical rationale directly to physicians, researchers, and investors. In 2025-2026, this channel is especially useful because oncology meetings drive peer review and trial visibility, and one strong poster or talk can shape follow-on interest fast.
Investor relations
Purple Biotech Ltd. uses investor relations as its main promotion tool because it had no commercial product sales in FY2025, so filings, investor decks, and calls do the work of market education. These updates explain pipeline progress, R&D use, and financing needs, which matters for a development-stage biotech with 0 product revenue.
Clinical trial disclosures
Purple Biotech Ltd. uses clinical trial disclosures as promotion by posting trial registrations and updates for its Phase 1b/2 and Phase 1/2 studies, which lets investors track progress without delay. That transparency supports credibility, since each update shows where a program stands, what milestones were met, and what comes next.
For a biotech with no product revenue, these filings do the marketing work: they build awareness, reduce uncertainty, and back the story with verifiable development data.
- Phase 1b/2 and Phase 1/2 visibility
- Trial status updates build trust
- Registration data supports oversight
Rebrand from Kitov Pharma
Purple Biotech Ltd. changed its name from Kitov Pharma Ltd. in December 2020, and that rebrand acted as a clear promotion signal and identity reset. It helped tie the Company Name to its oncology focus, which is the point of the move. For 2025/2026, the name still supports brand clarity in a competitive cancer-drug market.
Name change: December 2020
Signal: corporate promotion and reset
Fit: sharper oncology alignment
Purple Biotech Leans on PR and Congresses to Build Its Oncology Story
Purple Biotech Ltd. promotes its story through press releases, oncology congresses, investor relations, and clinical-trial updates. In FY2025 it had no product revenue, so these channels did the work of market education and catalyst tracking. The December 2020 name change from Kitov Pharma Ltd. still supports a clearer oncology identity in 2025/2026.
| Channel | 2025/2026 use |
|---|---|
| Press releases | Pipeline and trial news |
| IR and congresses | No sales; investor focus |
Price
No approved drug pricing
Purple Biotech Ltd. has no approved drug pricing yet because all programs remain clinical-stage, so there is no commercial list price for patients or payers. As of 2026, its pipeline still has no marketed product, so price is not a current 4P lever. Pricing will matter only after FDA or EMA approval, when reimbursement and launch strategy set the first real price.
Trial-sponsored access
Trial-sponsored access means Purple Biotech Ltd. supplies an investigational treatment inside clinical studies, so patients do not pay retail during the trial phase. The sponsor carries the development and study costs, and Purple Biotech Ltd. does not book product revenue from those doses. That pricing model fits a clinical-stage Company with no commercial launch yet.
Public market share price
As a public company, Purple Biotech Ltd.’s value is shown in its share price and market cap, not customer price. The stock is set by investors and can swing fast on trial data, cash runway, and biotech risk appetite. For a clinical-stage biotech, one data readout or financing update can move the shares sharply in a single session.
Future premium oncology pricing
If Purple Biotech Ltd. gets approval, its oncology biologics or targeted drugs would likely launch at a premium; many U.S. cancer therapies now exceed $100,000 per patient a year. Price will hinge on clear survival or response gains and payer coverage, so value-based pricing will matter most in the U.S. market.
Reimbursement pressure is real: in 2025, U.S. Part B and Part D drugs still faced heavy prior auth and rebate bargaining, so net price can move far below list. If clinical benefit is modest, pricing power weakens fast.
- Premium launch price is likely
- Benefit data will drive pricing
- U.S. reimbursement is decisive
- Net price may trail list price
Funding and dilution
For Purple Biotech Ltd., funding is the core price issue: clinical-stage biotechs usually pay for R&D with equity, so each raise can fund trials but also dilute existing holders. That means the real cost of building the business is not just cash spent, but the value given up through new shares.
- Equity raises fund R&D.
- Dilution can cut per-share value.
- Capital access lowers execution risk.
Purple Biotech: No Drug Price Yet, Just Clinical-Stage Funding
Purple Biotech Ltd. has no commercial drug price in 2026 because its pipeline is still clinical-stage, so price is not yet a live 4P lever. Any future launch price will depend on FDA or EMA approval, payer coverage, and measured benefit, while today funding still comes from equity and trial sponsorship, which can dilute holders.
| Price factor | 2026 status |
|---|---|
| Drug list price | None |
| Trial patient price | Retail-free |
| Main capital source | Equity raises |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.